Physician profile
Fred Morady
NPI 1659457612
$3,725.04
in general payments reported to CMS, 2019-2025
10 companies · $539 in 2025
The $539 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $211 · 2021: $247 · 2022: $434 · 2023: $740 · 2024: $837 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,764.09 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $245.17 | 2022-2024 | Breztri |
| Ardelyx, INC. | $133.58 | 2023 | Ibsrela |
| Astellas Pharma US INC | $124.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.72 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.85 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $116.26 | 2022 | |
| Genzyme Corporation | $64.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Morady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.